Program
aflibercept
Also written as “Aflibercept”, “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)” and “aflibercept injection (VEGF Trap-Eye, BAY86-5321)”.
Its studies are mostly in Macular Degeneration · Macular Edema · Colorectal Neoplasms · Lymphoma, Non-Hodgkin · Retinal Vein Occlusion, led by 15 companies.
Drug pageAflibercept: every studyMany companies study it; this page follows only the 86 they lead. All 268 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Regeneron Pharmaceuticalsits history only | 251 open or running | phase 4since Nov 2, 2012 | May 13, 2002 | none ahead |
| Bayer | 230 open or running | phase 4since Apr 10, 2014 | Mar 12, 2008 | none ahead |
| Sanofiits history only | 200 open or running | phase 3since May 16, 2006 | Jan 30, 2006 | none ahead |
| Novartisits history only | 40 open or running | phase 4since Jul 22, 2016 | Jul 22, 2016 | none ahead |
| Amgenits history only | 31 open or running | phase 3since Feb 13, 2020 | Feb 13, 2020 | Jul 31, 2027phase 3 · NCT07614776 |
| Sam Chun Dang Pharm.its history only | 20 open or running | phase 3since Jul 17, 2020 | Jul 17, 2020 | none ahead |
| AbbVieits history only | 11 open or running | phase 2since Mar 16, 2022 | Mar 16, 2022 | Jun 2031phase 2 · NCT05296447 |
| AO GENERIUMits history only | 11 open or running | phase 3since Sep 18, 2026 | Sep 18, 2026 | May 2028phase 3 · NCT07844148 |
| bioeq-gmbhits history only | 10 open or running | phase 3since Aug 11, 2020 | Aug 11, 2020 | none ahead |
| cinnagenits history only | 10 open or running | phase 3since Sep 18, 2022 | Sep 18, 2022 | none ahead |
| Exegenesis Bioits history only | 11 open or running | phase 1since Jan 30, 2025 | Jan 30, 2025 | Feb 2029phase 1 · NCT06817343 |
| formycon-agits history only | 10 open or running | phase 4since Nov 25, 2024 | Nov 25, 2024 | none ahead |
| Qilu Pharmaceuticalits history only | 10 open or running | phase 3since Apr 19, 2022 | Apr 19, 2022 | none ahead |
| Samsung Bioepisits history only | 10 open or running | phase 2since Sep 21, 2026 | Sep 21, 2026 | none ahead |
| the-emmes-company-llcits history only | 10 open or running | phase 3since Oct 22, 2013 | Oct 22, 2013 | none ahead |
Also a collaborator on its studies: REGENXBIO and Parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Bayer only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 7 studies since Mar 12, 2008.
- Apr 10, 2014Phase 4 study in Neovascular Macular DegenerationNCT02120950 · 333 enrolled · Australia, Germany, Hong Kong and more
- Nov 28, 2014Phase 4 study in Wet Macular DegenerationNCT02305238 · 288 enrolled · Japan
- Mar 18, 2015Phase 3 study in Glaucoma, NeovascularNCT02396316 · 54 enrolled · Japan
- Sep 2, 2015Phase 3 study in Macular DegenerationNCT02540954 · 336 enrolled · Austria, Canada, Czechia and more
- Oct 20, 20152 phase 4 studiesNCT02581995, NCT02581891
- Jun 10, 2016Phase 4 study in Retinal Vein OcclusionNCT02800642 · 162 enrolled · Australia, Canada, Denmark and more
- Jun 28, 2016Phase 3 study in Macular EdemaNCT02818998 · 463 enrolled · Austria, Canada, Czechia and more
- Aug 17, 2018Phase 3 study in Glaucoma, NeovascularNCT03639675 · 16 enrolled · Japan
- Jun 28, 20192 phase 3 studies in Retinopathy of PrematurityNCT04015180, NCT04004208
- Jul 21, 2022Named afliberceptINNProposed as its International Nonproprietary Name in WHO's List 127
- Jul 22, 2022Phase 4 study in Macular DegenerationNCT05473715 · 3 enrolled · Canada, United Kingdom
- Aug 19, 2022Phase 4 study in Diabetic Macular EdemaNCT05511038 · 100 enrolled · India
- Apr 28, 2023Phase 3 study in Macular Edema Secondary to Retinal Vein OcclusionNCT05850520 · 892 enrolled · United States, Australia, Austria and more
- May 15, 2024Phase 3 study in Diabetic Macular EdemaNCT06422507 · 333 enrolled · China, Hong Kong
- Sep 8, 2024Phase 4 study in Diabetic Macular EdemaNCT06591598 · 51 enrolled · Czechia, Hungary, Slovakia
TargetBeta
“Vascular endothelial growth factor A inhibitor; Placenta growth factor inhibitor”ChEMBL 37, by rule
Studies
All 23 Bayer leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06591598Diabetic Macular Edema · Czechia, Hungary, Slovakia | 4 | Completed | Oct 14, 2025 | 51 |
| NCT06422507Diabetic Macular Edema · China, Hong Kong | 3 | Completed | Dec 29, 2025 | 333 |
| NCT05850520Macular Edema Secondary to Retinal Vein Occlusion · United States, Australia, Austria and more | 3 | Completed | Nov 7, 2024 | 892 |
| NCT05511038Diabetic Macular Edema · India | 4 | Completed | Apr 16, 2024 | 100 |
| NCT05473715Macular Degeneration · Canada, United Kingdom | 4 | Terminated | Jul 11, 2023 | 3 |
| NCT04015180Retinopathy of Prematurity · Argentina, Belgium, Brazil and more | 3 | Completed | Sep 19, 2025 | 100 |
| NCT04004208Retinopathy of Prematurity · Argentina, Austria, Belgium and more | 3 | Completed | Feb 12, 2021 | 113 |
| NCT03639675Glaucoma, Neovascular · Japan | 3 | Completed | Feb 14, 2019 | 16 |
| NCT02818998Macular Edema · Austria, Canada, Czechia and more | 3 | Completed | Nov 13, 2018 | 463 |
| NCT02800642Retinal Vein Occlusion · Australia, Canada, Denmark and more | 4 | Completed | Jul 31, 2019 | 162 |
| NCT02581995Macular Edema · Austria, Canada, Czechia and more | 4 | Completed | Aug 9, 2017 | 560 |
| NCT02581891Macular Degeneration · Australia, Canada, France and more | 4 | Completed | Apr 26, 2019 | 287 |
| NCT02540954Macular Degeneration · Austria, Canada, Czechia and more | 3 | Completed | Dec 24, 2019 | 336 |
| NCT02396316Glaucoma, Neovascular · Japan | 3 | Completed | Jun 16, 2016 | 54 |
| NCT02305238Wet Macular Degeneration · Japan | 4 | Completed | Dec 22, 2016 | 288 |
| NCT02120950Neovascular Macular Degeneration · Australia, Germany, Hong Kong and more | 4 | Completed | Aug 12, 2016 | 333 |
| NCT01783886Macular Edema · China, Hong Kong, Korea, Republic of and more | 3 | Completed | Mar 2015 | 381 |
| NCT01512966Macular Edema · Japan | 3 | Completed | Sep 2013 | 73 |
| NCT01482910Macular Degeneration · China | 3 | Completed | Mar 2014 | 304 |
| NCT01331681Diabetes Mellitus · Australia, Austria, Czechia and more | 3 | Completed | Jun 3, 2013 | 406 |
| NCT01249664Myopia, Degenerative · Hong Kong, Japan, Korea, Republic of and more | 3 | Completed | Feb 2013 | 122 |
| NCT01012973Retinal Vein Occlusion · Australia, Austria, France and more | 3 | Completed | Feb 2011 | 177 |
| NCT00637377Macular Degeneration · Argentina, Australia, Austria and more | 3 | Completed | Sep 2010 | 1,240 |
How it is read
Names in the registry
- “Aflibercept”, 9 entries
- “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)”, 8 entries
- “aflibercept injection (VEGF Trap-Eye, BAY86-5321)”, 8 entries
- “aflibercept”, 7 entries
- “Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)”, 7 entries
Codes read as this program: BAY865321, SCD411.
Conditions, from the studies’ own filings
- Macular Degeneration, 28 studies
- Macular Edema, 15 studies
- Colorectal Neoplasms, 8 studies
- Lymphoma, Non-Hodgkin, 5 studies
- Retinal Vein Occlusion, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.